A systematic review of the protective role of swertiamarin in cardiac and metabolic diseases

Leong, Xin Yu; Veeraveedu, Punniyakoti T.; Pandey, Manisha; Ramamurthy, Srinivasan

doi:10.1016/j.biopha.2016.10.044

Cited by 36 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is soluble in an aqueous solution and well-known for its anti-inflammatory, anaesthetic, antihistamine, anticonvulsant properties ( Lim et al, 2006 ). Further, swertiamarin, a secoiridoid glycoside present within the extract of this plant, is accountable for its analgesic property ( Leong et al, 2016 ). Thus, the above-mentioned nutraceutical potential of this plant compels us to decipher its anticancer efficacy against lung cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Swertia chirayita suppresses the growth of non-small cell lung cancer A549 cells and concomitantly induces apoptosis via downregulation of JAK1/STAT3 pathway

Ahmad

Tiwari

Almeleebia

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

Lung carcinoma is the leading cause of cancer-related mortalities worldwide, and present therapeutical interventions are not successful enough to treat this disease in many cases. Recent years have witnessed a surge in exploring natural compounds for their antiproliferative efficacy to expedite the characterization of novel anticancer chemotherapeutics. Swertia chirayita is a valued medicinal herb and possess intrinsic pharmaceutical potential. However, elucidation of its anticancer effects at molecular levels remains unclear and needs to be investigated. We assessed the anticancer and apoptotic efficacy of S . chirayita ethanolic extract ( Sw -EtOH) on non-small cell lung cancer (NSCLC) A549 cells during this exploratory study. The results elucidated that S. chirayita extract induced toxic effects within lung cancer cells by ~1 fold during cytotoxicity and LDH release assay at a 400 μg/ml concentration. Sw -EtOH extract elevates the level of ROS, resulting in the disruption of Δψm and release of cytosolic cytochrome c by 3.15 fold. Activation of caspases-3, -8 & -9 also escalated by ~1 fold, which further catalyze the augmentation of PARP cleavage (~3 folds), resulting in a four-fold increase in Sw -EtOH induced apoptosis. The gene expression analysis further demonstrated that Sw -EtOH extracts inhibited JAK1/STAT3 signaling pathway by down-regulating the levels of JAK1 and STAT3 to nearly half a fold. Treatment of Sw -EtOH modulates the expression level of various STAT3 associated proteins, including Bcl-XL, Bcl-2, Mcl-1, Bax, p53, Fas, Fas-L, cyclinD1, c-myc, IL-6, p21 and p27 in NSCLC cells. Thus, our study provided a strong impetus that Sw -EtOH holds the translational potential of being further evaluated as efficient cancer therapeutics and a preventive agent for the management of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Swertia chirayita suppresses the growth of non-small cell lung cancer A549 cells and concomitantly induces apoptosis via downregulation of JAK1/STAT3 pathway

Ahmad

Tiwari

Almeleebia

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

show abstract

“…STM is a secoiridoid glycoside mainly isolated from Enicostemma species and has demonstrated a wide variety of biological activities such as anti-inflammatory, anti-pyretic, anti-microbial, anti-malarial, and anti-diabetic activity [10][11][12][13][14][15][16]. However, the anti-tumor activity of STM has seldom been reported.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of differentially expressed genes in hepatocellular carcinoma cells exposed to Swertiamarin

et al. 2019

View full text Add to dashboard Cite

Aim: To explore gene expression profiling in hepatocellular carcinoma (HCC) cells exposed to swertiamarin. Methods: Cell viability, apoptosis and invasion were examined in HepG2 cells after swertiamarin treatment. Tumor growth of SK-Hep-1 cells xenografted in nude mice was monitored after swertiamarin treatment. Total RNA was isolated from HepG2 cells treated with swertiamarin for microarray analysis. The data of microarray were analyzed by bioinformatics. Results: Swertiamarin treatment decreased the viability and invasion while increased the apoptosis of HepG2 cells, and significantly inhibited the growth of SK-Hep-1 cells xenografted in nude mice. Pathway and biological process analysis of differentially expressed genes (DEGs) in swertiamarin treated HepG2 cells showed that PI3k-Akt was the most significant regulated pathway. 47 targets of swertiamarin were predicted by CGBVS while 21 targets were predicted by 3NN. Notably, 8 targets were predicted as the targets of swertiamarin by both programs, including two prominent targets JUN and STAT3. A large range of DEGs induced by swertiamarin could be regulated by JUN and STAT3. Conclusion: Swertiamarin treatment led to significant changes in the expression of a variety of genes that modulate cell survival, cell cycle progression, apoptosis, and invasion. Moreover, most of these genes can be clustered into pathway networks such as PI3K, JUN, STAT3, which are predicted targets of swertiamarin. Further confirmation of these targets will reveal the anti-tumor mechanisms of swertiamarin and facilitate the development of swertiamarin as a novel agent for cancer prevention and treatment.

show abstract

“…In another example, the monoacetylation of (Z)-5-ethylidene-8-hydroxy-7-((3-hydroxypyridin-4-yl) methyl)-3,4,5,6,7,8-hexahydro-1H-pyrano [3,4-c]pyridin-1-one (38,Scheme 15), derived from the iridiod-type aglycon of multi-active swertiamarine [137][138][139], is reported in a patent from Jiangxi Science & Technology Normal University granted in 2018 [140]. In this patent, compound 38 is obtained by a controlled fermentation of Swertia mussoti dry roots using cells from Aspergillus niger, isolated and acylated with vinyl acetate and Novozym 435 to provide 39 (acylated only in the aromatic OH group, no yield reported), an alkaloid which anti-hepatitis and anticancer activity seems to be very promising.…”

Section: Other Recently-granted Patents Using Lipasesmentioning

confidence: 99%

Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019)

Marı́a¹,

Gonzalo

Alcántara

2019

Catalysts

View full text Add to dashboard Cite

The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities. This paper analyses the intellectual property activities of the last five years (2014–2019) with a specific focus on biocatalysis applied to asymmetric synthesis. Furthermore, to reflect the inventive and innovative steps, only patents that were granted during that period are considered. Patent searches using several keywords (e.g., enzyme names) have been conducted by using several patent engine servers (e.g., Espacenet, SciFinder, Google Patents), with focus on granted patents during the period 2014–2019. Around 200 granted patents have been identified, covering all enzyme types. The inventive pattern focuses on the protection of novel protein sequences, as well as on new substrates. In some other cases, combined processes, multi-step enzymatic reactions, as well as process conditions are the innovative basis. Both industries and academic groups are active in patenting. As a conclusion of this survey, we can assert that biocatalysis is increasingly recognized as a useful tool for asymmetric synthesis and being considered as an innovative option to build IP and protect synthetic routes.

show abstract

A systematic review of the protective role of swertiamarin in cardiac and metabolic diseases

Cited by 36 publications

References 48 publications

Swertia chirayita suppresses the growth of non-small cell lung cancer A549 cells and concomitantly induces apoptosis via downregulation of JAK1/STAT3 pathway

Swertia chirayita suppresses the growth of non-small cell lung cancer A549 cells and concomitantly induces apoptosis via downregulation of JAK1/STAT3 pathway

Bioinformatics analysis of differentially expressed genes in hepatocellular carcinoma cells exposed to Swertiamarin

Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019)

Contact Info

Product

Resources

About